Artiva Accounts Payable from 2010 to 2025
ARTV Stock | 6.53 0.25 3.69% |
Accounts Payable | First Reported 2010-12-31 | Previous Quarter 552.6 K | Current Value 1.1 M | Quarterly Volatility 604.3 K |
Check Artiva Biotherapeutics, financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Artiva Biotherapeutics,'s main balance sheet or income statement drivers, such as Net Interest Income of 3.1 M, Interest Income of 3.1 M or Depreciation And Amortization of 2.7 M, as well as many indicators such as Price To Sales Ratio of 3.66, Dividend Yield of 0.0 or Days Sales Outstanding of 20.93. Artiva financial statements analysis is a perfect complement when working with Artiva Biotherapeutics, Valuation or Volatility modules.
Artiva | Accounts Payable |
Latest Artiva Biotherapeutics,'s Accounts Payable Growth Pattern
Below is the plot of the Accounts Payable of Artiva Biotherapeutics, Common over the last few years. An accounting item on the balance sheet that represents Artiva Biotherapeutics, obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Artiva Biotherapeutics, are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. It is the amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities. Artiva Biotherapeutics,'s Accounts Payable historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Artiva Biotherapeutics,'s overall financial position and show how it may be relating to other accounts over time.
Accounts Payable | 10 Years Trend |
|
Accounts Payable |
Timeline |
Artiva Accounts Payable Regression Statistics
Arithmetic Mean | 1,776,788 | |
Geometric Mean | 1,634,631 | |
Coefficient Of Variation | 34.01 | |
Mean Deviation | 514,542 | |
Median | 2,151,000 | |
Standard Deviation | 604,299 | |
Sample Variance | 365.2B | |
Range | 1.6M | |
R-Value | (0.79) | |
Mean Square Error | 145B | |
R-Squared | 0.63 | |
Significance | 0.0002 | |
Slope | (100,706) | |
Total Sum of Squares | 5.5T |
Artiva Accounts Payable History
About Artiva Biotherapeutics, Financial Statements
Artiva Biotherapeutics, investors use historical fundamental indicators, such as Artiva Biotherapeutics,'s Accounts Payable, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Artiva Biotherapeutics,. Please read more on our technical analysis and fundamental analysis pages.
Last Reported | Projected for Next Year | ||
Accounts Payable | 552.6 K | 1.1 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Artiva Stock Analysis
When running Artiva Biotherapeutics,'s price analysis, check to measure Artiva Biotherapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Artiva Biotherapeutics, is operating at the current time. Most of Artiva Biotherapeutics,'s value examination focuses on studying past and present price action to predict the probability of Artiva Biotherapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Artiva Biotherapeutics,'s price. Additionally, you may evaluate how the addition of Artiva Biotherapeutics, to your portfolios can decrease your overall portfolio volatility.